Harpoon Therapeutics
Chatan Charan is an experienced pharmaceutical development professional with a robust background in technical and manufacturing operations. Currently serving as Senior Vice President at Harpoon Therapeutics, Chatan has held various key positions at Nektar Therapeutics, including Vice President of Pharmaceutical Development, Executive Director of Pharmaceutical Development, and Senior Director of Product Development. Earlier career experiences include roles as a Staff Research Associate at Scios, Associate Chemist at Midwest Research Institute, and Chemist at Mast Immunosystems. Chatan holds a Ph.D. in Pharmaceutics from the University of Sydney and has education from the University of San Francisco.
This person is not in any teams
This person is not in any offices
Harpoon Therapeutics
Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC), platform, Harpoon is developing a pipeline of novel T cell engagers, or TriTACs, initially focused on the treatment of solid tumors and hematologic malignancies. Harpoon's first drug candidate, HPN424, is currently in Phase 1 clinical trial as a treatment for prostate cancer.